Could a diabetes drug shield ICU survivors from deadly heart and kidney failure?

NCT ID NCT07025629

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Apr 29, 2026 · Updated 16 times

Summary

This study tests whether dapagliflozin, a drug already used for diabetes and heart failure, can reduce death and serious heart or kidney problems in people leaving the intensive care unit (ICU). About 600 adults who needed a breathing machine or blood pressure support in the ICU and have high heart or kidney risk markers will receive either the drug or a placebo for up to 12 months. The goal is to see if this approach can improve long-term survival and prevent hospital readmissions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE AND CHRONIC KIDNEY DISEASE POST-ICU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital Saint Louis
RECRUITING

Paris, 75010, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Saint Louis Hospital
NOT_YET_RECRUITING

Paris, 75010, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEART FAILURE AND CHRONIC KIDNEY DISEASE POST-ICU